INmune Bio received written alignment from the UK MHRA on its 2026 plan to seek conditional marketing authorization for CORDStrom™ (Ebstrocel™) to treat Recessive Dystrophic Epidermolysis Bullosa (RDEB), a rare genetic skin disorder. MHRA agreed on the manufacturing, clinical, and non-clinical data requirements and recognized Phase 2 trial data showing meaningful symptom relief, especially for pain and itching, supporting its use as a chronic or intermittent therapy. The company is incorporating MHRA feedback into its Phase 3 trial design and aims to submit applications in the UK, EU, and US by late 2026 or early 2027. This regulatory milestone reduces risk and provides a clear path for potential approval of this novel cell therapy in an ultra-rare disease with limited treatment options.
The global automotive microcontrollers market is projected to grow from USD 15.49 billion in 2025 to USD 34.31 billion by 2035, at a CAGR of 8.28%. Growth is fueled by increasing adoption of advanced driver-assistance systems (ADAS), vehicle electrif...
Alpaca, a brokerage infrastructure startup, secured $435 million in funding to enter prime brokerage services, challenging traditional Wall Street firms. The company’s API supports 94% of US equities and powers tokenized stocks for Kraken. Alpaca’s t...
Raymond James Financial's rating was raised to "Buy" after positive investor event disclosures and a promising preview of its upcoming quarterly results. The company is expected to exceed earnings per share consensus for Q3 FY26, driven by strong per...
Bitcoin and Ethereum experienced combined outflows exceeding $59 million as traders moved funds into stablecoins like USDT and fiat currencies, signaling a cautious stance in the crypto market. This rotation reflects a short-term defensive strategy, ...
Whales have accumulated 70 million XRP over the past week, showing strong confidence despite XRP's price consolidating below resistance levels. The XRP Ledger surpassed 8 million activated accounts, indicating growing network adoption across payments...
